🚧 Under construction — VoTechWorks is being built. A free tech program — complimentary, as our commitment to get America working.
voTechWorksGrade 13 · a vocational technology learning center, by urbanicity
newSchoolWorks.com › VoTechWorks › Health & Personal Services › Pharmacy Technician › Compounding: Non-Sterile, Sterile and Hazardous (USP <795>, <797>, <800>) › Lesson 9
HLT-PHAR41-04 · Lesson 9 · 15 clock hours · lab

Compounded sterile preparations and beyond-use dates

Objective. Prepare IV admixtures and assign beyond-use dates by the USP <797> category of the preparation.

⚠ Pending professional review

This lesson, its worked examples and its practice questions has not yet been verified by a licensed pharmacist or by a certification or approval body. It is a study draft and may contain errors. Do not use it to make decisions about any patient or medication. Always follow your instructor, your supervising professional, and current official references and regulations.

VoTechWorks program approval and accreditation are still in progress. Credentials are issued only by the certifying bodies named in each program, after their own exams.

Compounded Sterile Preparations and Beyond-Use Dates

What Is a Compounded Sterile Preparation?

A compounded sterile preparation (CSP) is any preparation intended to be sterile that is made by combining, admixing, diluting, reconstituting, or repackaging ingredients outside the original manufacturer's container. Common examples include IV piggybacks (small-volume parenteral bags), large-volume parenteral solutions, syringes for injection, epidural preparations, and ophthalmic drops. Because these products bypass the body's normal defenses against infection when administered, contamination can cause serious patient harm or death. Every step of the compounding process must protect sterility.

USP Chapter <797> Overview

USP General Chapter <797> establishes the minimum practice and quality standards for CSPs in the United States. Regulatory agencies, state boards of pharmacy, and accreditation bodies use <797> as the benchmark. The chapter governs personnel training and competency, facilities and equipment (including ISO-classified cleanrooms and primary engineering controls), garbing and hand hygiene, environmental monitoring, sterility and endotoxin testing, and — critically for today's lab — beyond-use dates (BUDs).

The most recent major revision to <797> took effect in 2023. It introduced a category-based BUD system that replaced the older risk-level framework.

The Three Categories of CSPs Under USP <797>

USP <797> (2023) places every CSP into one of three categories based on the conditions under which it was prepared. The category directly determines the maximum allowable BUD.

Category 1 applies to CSPs compounded in facilities that do not meet all the facility, environmental monitoring, and personnel testing requirements of <797>. This includes preparations made at the patient bedside, in a non-ISO–classified area, or in a facility that has not implemented a full <797>-compliant program. Category 1 BUDs are short — 12 hours or less at controlled room temperature (CRT) or 24 hours or less under refrigeration.

Category 2 applies to CSPs compounded in a fully <797>-compliant facility: a properly designed cleanroom suite with an ISO 7 buffer area and an ISO 5 primary engineering control (such as a laminar airflow workbench or biological safety cabinet), with all required personnel training, garbing competencies, gloved fingertip and surface sampling completed and passed, and a robust environmental monitoring program in place. Category 2 BUDs are longer and depend on whether a preparation is sterility-tested, the storage conditions, and the nature of the ingredients. Aqueous CSPs that are not sterility-tested have defined maximum BUDs (for example, up to 4 days at CRT, up to 10 days refrigerated, and up to 45 days frozen — exact values are found in the <797> tables and must be verified in the current chapter). Preparations that undergo sterility testing per USP standards can receive extended BUDs per the chapter tables.

Category 3 (introduced in 2023) applies to extended-BUD CSPs where the facility meets Category 2 requirements AND the preparation undergoes additional testing (sterility and bacterial endotoxins at minimum) per the chapter requirements. Category 3 allows the longest BUDs. Always consult the current USP <797> tables for specific numeric limits.

Assigning a Beyond-Use Date

To assign a BUD correctly, work through these questions in order:

1. Does the facility meet full USP <797> infrastructure requirements? If no, assign Category 1 BUD.

2. Does the preparation undergo the required sterility and endotoxin testing for Category 3? If yes and the facility qualifies, Category 3 BUD may apply.

3. Otherwise, apply Category 2 BUD limits from the USP <797> tables, matching the storage condition (room temperature, refrigerated, or frozen) to the correct row.

4. Check ingredient-specific limits. If a drug's manufacturer labeling or stability data requires a shorter dating period than the category allows, use the shorter date. The BUD can never exceed established stability data.

5. Label clearly. The label must state the BUD as a specific date and time (not just hours).

IV Admixture Preparation: Key Safety Points

Working in the Cleanroom

Maintain ISO 5 conditions at the critical site (needle tip, vial septum, bag port). Keep your hands and materials within the direct compounding area. Minimize interruptions and talking. If you break aseptic technique — touch a non-sterile surface, sneeze, or interrupt the process — stop, re-garb as required, and start again. Patient safety depends on your discipline at every step.

Key terms10

Compounded Sterile Preparation (CSP)A preparation intended to be sterile that is made by combining, admixing, diluting, or repackaging ingredients outside the original manufacturer's container.
Beyond-Use Date (BUD)The date and time after which a CSP may no longer be used, assigned based on USP <797> category, storage conditions, and ingredient stability data.
USP <797>The United States Pharmacopeia general chapter that sets minimum standards for the preparation, labeling, quality, and storage of compounded sterile preparations.
Category 1 CSPA CSP prepared in a facility that does not fully meet USP <797> infrastructure requirements; carries the shortest allowable BUDs (up to 12 hours at room temperature or 24 hours refrigerated).
Category 2 CSPA CSP prepared in a fully USP <797>–compliant facility with ISO-classified cleanrooms and a complete environmental monitoring program; eligible for longer BUDs from the USP <797> tables.
Primary Engineering Control (PEC)A device such as a laminar airflow workbench or biological safety cabinet that provides an ISO 5 environment to protect the critical site during compounding.
Aseptic TechniqueThe set of practices used during compounding to prevent microbial contamination of a preparation, including proper garbing, hand hygiene, surface disinfection, and manipulation within ISO 5 airflow.
ISO ClassificationA rating system (ISO 5, 7, 8, etc.) that describes the maximum allowable airborne particle count in a cleanroom area; lower numbers indicate cleaner environments. ISO 5 is required at the critical site.
Large-Volume Parenteral (LVP)An IV bag containing 100 mL or more of sterile solution, often used to deliver fluids, electrolytes, or medications over an extended infusion period.
Small-Volume Parenteral (SVP)An IV piggyback bag typically containing less than 100 mL of solution used to administer a drug dose over a short infusion time (e.g., 30–60 minutes).

Worked examples4

1. A technician prepares a sodium chloride 0.9% IV bag with an antibiotic additive in a fully USP <797>–compliant Category 2 facility. The preparation will be stored under refrigeration and will not undergo sterility testing. The drug manufacturer's stability data supports 7 days refrigerated. The USP <797> Category 2 table allows up to 10 days refrigerated for this type of aqueous preparation. The preparation is completed on Monday, June 2 at 10:00 AM. What is the correct BUD?
  1. Step 1 – Identify the category: The facility meets all USP <797> requirements → Category 2.
  2. Step 2 – Identify storage condition: Refrigerated.
  3. Step 3 – Find the USP <797> Category 2 maximum BUD for a refrigerated, non-sterility-tested aqueous preparation: up to 10 days.
  4. Step 4 – Check drug stability: manufacturer data supports only 7 days refrigerated.
  5. Step 5 – Apply the more restrictive limit: 7 days (shorter of 7 days and 10 days).
  6. Step 6 – Calculate: June 2 + 7 days = June 9 at 10:00 AM.
  7. Step 7 – Write BUD as date and time: June 9, 10:00 AM.
Answer: BUD: June 9 at 10:00 AM (7 days refrigerated, limited by drug stability data).
2. A technician prepares a morphine sulfate syringe in a facility that does NOT have an ISO-classified cleanroom and has not completed USP <797> environmental monitoring. The syringe will be stored at controlled room temperature. What is the maximum BUD the technician may assign?
  1. Step 1 – Determine category: Facility does not meet USP <797> infrastructure requirements → Category 1.
  2. Step 2 – Identify storage condition: Controlled room temperature.
  3. Step 3 – Apply Category 1 BUD limit: 12 hours or less at controlled room temperature.
  4. Step 4 – Assign BUD: no more than 12 hours from time of preparation.
Answer: Maximum BUD is 12 hours at controlled room temperature (Category 1).
3. A technician needs to add 20 mEq of potassium chloride (KCl) to a 1,000 mL bag of dextrose 5% in water (D5W). KCl is available as a 2 mEq/mL concentration in a 30 mL vial. How many milliliters of KCl must be withdrawn?
  1. Step 1 – Identify desired dose: 20 mEq.
  2. Step 2 – Identify available concentration: 2 mEq/mL.
  3. Step 3 – Set up ratio: Volume (mL) = Desired dose (mEq) ÷ Concentration (mEq/mL).
  4. Step 4 – Calculate: Volume = 20 mEq ÷ 2 mEq/mL = 10 mL.
  5. Step 5 – Verify vial has enough: 30 mL vial × 2 mEq/mL = 60 mEq available; 10 mL needed. ✓
Answer: Withdraw 10 mL of KCl 2 mEq/mL and inject into the D5W bag.
4. A pharmacist asks a technician to prepare vancomycin 1,250 mg in a 250 mL NS piggyback. Vancomycin is reconstituted and available as a 50 mg/mL solution. How many milliliters of vancomycin solution should be added to the bag?
  1. Step 1 – Identify desired dose: 1,250 mg.
  2. Step 2 – Identify available concentration: 50 mg/mL.
  3. Step 3 – Calculate volume: Volume = 1,250 mg ÷ 50 mg/mL = 25 mL.
  4. Step 4 – Confirm: 25 mL × 50 mg/mL = 1,250 mg. ✓
  5. Step 5 – Note: When 25 mL is added to a 250 mL bag, the final volume will be approximately 275 mL. Confirm this is acceptable per the order before proceeding.
Answer: Withdraw 25 mL of vancomycin 50 mg/mL and inject into the 250 mL NS bag.
In class: IV bag admixture · Syringe preparation · BUD assignment exercise
Materials: IV bags, additives, labels
Check: Admixture practical: competent

Practice check8

Answer each question, then check it. Nothing is recorded; this is your own practice.

Patient Safety and Quality Assurance
1. A compounded sterile preparation is made in a facility without ISO-classified cleanrooms or a USP <797> environmental monitoring program. At room temperature, the maximum beyond-use date under USP <797> is:
Medications
2. Which USP chapter specifically governs the standards for compounded sterile preparations, including beyond-use dating and cleanroom requirements?
Patient Safety and Quality Assurance
3. When assigning a beyond-use date to a Category 2 CSP, the manufacturer's stability data indicates 5 days refrigerated, but the USP <797> Category 2 table allows up to 10 days refrigerated. The technician should assign a BUD of:
Patient Safety and Quality Assurance
4. During IV admixture preparation in the laminar airflow workbench, a technician accidentally touches the needle tip to the edge of the biosafety cabinet. The correct action is to:
Order Entry and Processing
5. A technician must add 15 mEq of potassium chloride to an IV bag. The available vial contains KCl at 2 mEq/mL. How many milliliters should be drawn up?
Medications
6. Which ISO classification is required at the critical site (e.g., needle tip, vial septum) during sterile compounding under USP <797>?
Federal Requirements
7. Before a compounded sterile preparation may leave the compounding area for patient use, it must be:
Patient Safety and Quality Assurance
8. Under the 2023 revision of USP <797>, which category allows the longest beyond-use dates because it requires both full facility compliance AND additional sterility and endotoxin testing?
Record this lesson on my transcript. Sign in with your key and enrollment email to record lessons (enroll free if you have no key). This page stays open to read and practise.
← Previous lessonTop-200 drugsNext lesson →